1) Borison RL:The role of cognition in the risk--benefit and safety analysis of antipsychotic medication. Acta Psychiatr Scand (Suppl) 389:5-11, 1996
2) 古谷博和,山口通子,三好甫,他:クエン酸タンドスピロンの奏効したパーキンソン症候群の1例.Prog Med 22:233-238,2002
3) 石田昭彦,関口恵史,安澄文興:運動障害を主とした高齢者パーキンソン病に対する5-HT 1Aセロトニン受容体作動薬の効果.治療 82:2664-2668,2000
4) Janno S, Holi M, Tuisku K, et al:Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 161:160-163, 2004
5) Kapur S, Remington G:Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466-476, 1996
6) Matsubara K, Shimizu K, Suno M, et al:Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res 1112:126-133, 2006
7) Ohno Y, Shimizu S, Imaki J, et al:Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test. Prog Neuropsychopharmacol Biol Psychiatry 32:1302-1307, 2008
8) Robinson DG, Woerner MG, Alvir JM, et al:Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 57:209-219, 2002
9) Sumiyoshi T, Higuchi Y, Matsui M, et al:Effective adjunctive use of tandospirone with perospirone for enhancing verbal memory and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31:965-967, 2007